Preprint Post-COVID cognitive deficits at 1 year are global and associated w/elevated brain injury markers and grey matter vol reduction:... 2024 Michael et al

We report one-year cognitive, serum biomarker, and neuroimaging findings in 351 patients.

Post-COVID cognitive deficits at one year are global and associated with elevated brain injury markers and grey matter volume reduction: national prospect study, 2024

The spectrum, pathophysiology, and recovery trajectory of persistent post-COVID-19 cognitive deficits are unknown, limiting our ability to develop prevention and treatment strategies. We report the one-year cognitive, serum biomarker, and neuroimaging findings from a prospective, national longitudinal study of cognition in 351 COVID-19 patients who had required hospitalisation, compared to 2,927 normative matched controls.

Cognitive deficits were global and associated with elevated brain injury markers and reduced anterior cingulate cortex volume one year after admission.

The severity of the initial infective insult, post-acute psychiatric symptoms, and a history of encephalopathy were associated with greatest deficits. There was strong concordance between subjective and objective cognitive deficits. Treatment with corticosteroids during the acute phase appeared protective against cognitive deficits. Together, these findings support the hypothesis that brain injury in moderate to severe COVID-19 is immune-mediated, and should guide the development of therapeutic strategies.

https://www.researchsquare.com/article/rs-3818580/v1

 

Alan Carson is one of the authors.

 

https://twitter.com/user/status/1744668910023057634

 

The old causation switcheroo.

 

Trial By Error: Study Finds “Elevated Brain Injury Markers and Reduced Grey Matter Volume” a Year After Hospitalization for COVID-19

A British study of neurological sequelae in patients many months after hospitalization for COVID-19 has found that “post acute cognitive deficits…were associated with elevated brain injury markers in serum and reduced grey matter volume,” according to a pre-print posted earlier this week. (A pre-print is a paper that has not yet been peer-reviewed and published by a journal.)

The pre-print is part of the COVID-19 Clinical Neuroscience Study (COVID-CNS), a £2.3 million project funded by UK Research and Innovation, a non-departmental public organization. COVID-CNS, designed to investigate the neurological and neuropsychiatric complications of COVID-19, is led by researchers at the University of Liverpool and King’s College London. In late December, a paper from a different team of COVID-CNS researchers—”Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses”–was published in Nature Communications.

The pre-print study, titled “Post-COVID cognitive deficits at one year are global and associated with elevated brain injury markers and grey matter volume reduction: national prospective study,” is currently under review at Nature Portfolio. (That’s not a single journal but an umbrella for many journals published by Nature.)

https://virology.ws/2024/01/12/tria...me-a-year-after-hospitalization-for-covid-19/